Archive for the ‘mol cell endocrinology’ Category
A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.
Our count for Kato has now risen to 39; we added five retraction notices to our count for Kato last month. These notices follow an investigation at the University of Tokyo, where Kato used to work, which found 43 papers contained “likely altered or forged materials,” according to a 2013 news article from The Asahi Shimbun.
Here’s the retraction note for “1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP271B1 gene,” published in Molecular and Cellular Endocrinology:
Terry S. Elton, a researcher at Ohio State University in Columbus who studies genetic expression in various heart conditions and Down syndrome, has been sanctioned by the U.S. Office of Research Integrity for fabricating and/or falsifying data in a number of NIH grants and resulting papers.
According to an OSU statement sent to Retraction Watch last night, it was an anonymous whistleblower who alerted the university to the potential misconduct in July 2010. The ORI report notes that he two OSU investigations, along with the ORI investigation, found that Elton: Read the rest of this entry »